- Home
- TRC vs ZVRA Comparison
TRC vs ZVRA Comparison
Compare TRC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | ZVRA |
|---|---|---|
| Founded | 1843 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.8M | 472.9M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TRC | ZVRA |
|---|---|---|
| Price | $19.88 | $10.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 79.8K | ★ 663.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | $37,830,000.00 | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $7.70 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $15.31 | $6.85 |
| 52 Week High | $19.77 | $13.16 |
Technical Indicators
Market Signals| Indicator | TRC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.58 | 68.59 |
| Support Level | $18.10 | $10.69 |
| Resistance Level | N/A | $11.19 |
| Average True Range (ATR) | 0.32 | 0.39 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 90.70 | 91.29 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.